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Essentials
• Congenital afibrinogenemia causes a potentially life-
threatening bleeding and clotting tendency.
• Two human fibrinogen concentrates (HFCs) were com-
pared in a randomized pharmacokinetic study.
• Bioequivalence was not shown for AUCnorm, which was
significantly larger for the new HFC.
• Increases in clot strength were comparable, and no
thromboses or deaths occurred in the study.
Summary. Background: Human fibrinogen concentrate
(HFC) corrects fibrinogen deficiency in congenital a-/
hypofibrinogenemia. Objectives: To assess pharmacoki-
netics (PK), effects on thromboelastometry maximum
clot firmness (MCF), and safety of a new double virus-
inactivated/eliminated, highly purified HFC vs. active
control. Patients/Methods: In this multinational, ran-
domized, phase II, open-label, crossover study in 22 con-
genital afibrinogenemia patients aged ≥ 12 years,
70 mg kg1 of new HFC (FIBRYGA, Octapharma AG)
or control (Haemocomplettan P/RiaSTAPTM, CSL
Behring GmbH) were administered, followed by cross-
over to the other concentrate. Fibrinogen activity, PK
and MCF in plasma were assessed. Results: The
concentrates were not bioequivalent for the primary end-
point, AUCnorm (mean ratio, 1.196; 90% confidence
interval [CI], 1.117, 1.281). Remaining PK parameters
(Cmaxnorm, IVR, t1/2, MRT) reflected bioequivalence
between concentrates, except for clearance (mean ratio,
0.836; 90% CI, 0.781, 0.895) and Vss (mean ratio, 0.886;
90% CI, 0.791, 0.994). Mean AUCnorm was significantly
larger for the new HFC (1.62  0.45 vs.
1.38  0.47 h kg g L1 mg1, P = 0.0001) and mean
clearance was significantly slower (0.665  0.197 vs.
0.804  0.255 mL h1 kg1, P = 0.0002). Mean MCF
increased from 0 mm to 9.68 mm (new HFC) and
10.00 mm (control) 1-hour post-infusion (mean differ-
ence, 0.32 mm; 95% CI, 1.70, 1.07, n.s.). No deaths,
thromboses, viral seroconversions or serious related
adverse events occurred. Conclusions: Bioequivalence was
not demonstrated for AUCnorm, clearance and Vss.
Larger AUCnorm and slower clearance were observed for
the new HFC. Remaining pharmacokinetic parameters
reflected bioequivalence to control. Safety profiles and
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increases in clot strength were comparable between
concentrates.
Keywords: afibrinogenemia; comparative study; congenital;
fibrinogen; pharmacokinetics.
Introduction
Fibrinogen, also known as coagulation factor I, plays a cen-
tral role in hemostasis, promoting clot formation and plate-
let aggregation [1]. Following bleeding and activation of the
coagulation cascade the substrate fibrinogen is cleaved by
thrombin, yielding fibrin monomers that polymerize and
subsequently are cross-linked to form a stable, insoluble lat-
tice with platelets, and red and white blood cells, thus
impeding blood loss. In addition, fibrin itself has a signifi-
cant thrombin binding potential, for which reason it was
named antithrombin I [1]. Fibrinogen is the most abundant
clotting factor in the human circulation, with normal con-
centrations usually ranging from 1.5 to 4.5 g L1 [2], and
has a half-life of approximately 4 days [3].
Inherited defects of fibrinogen can affect either the
quantity (hypofibrinogenemia and afibrinogenemia) or the
quality (dysfibrinogenemia) of circulating fibrinogen.
Afibrinogenemia (i.e. lack of detectable fibrinogen in the
plasma) is the rarest and most severe form and has an
estimated incidence of approximately 1:1 000 000 [4]. It is
often diagnosed in the neonatal period, with 85% of cases
presenting with umbilical cord bleeds [5]. Patients with
afibrinogenemia have a highly variable bleeding tendency
that can be severe, including life-threatening bleeding and
spontaneous/trauma-related bleeds [3].
When supplementing fibrinogen levels in patients with
a/hypofibrinogenemia to treat or prevent bleeding, the
therapeutic goal is to achieve a plasma level of 1 to
1.5 g L1, depending on the severity of the bleeding chal-
lenge [6]. In a survey based on data from 100 patients
with inherited a/hypofibrinogenemia, the fibrinogen level
most frequently recommended for on-demand treatment
of minor bleeding was 1 g L1, whereas the target for
major bleeding (e.g. CNS-related) was 1.5 g L1 [6].
Human fibrinogen concentrate (HFC) is the treatment of
choice for fibrinogen replacement in patients with congenital
fibrinogen deficiency [7–9]. Cryoprecipitate is used for sup-
plementation of fibrinogen in some countries; however,
despite some progress in the use of solvent-detergent meth-
ods to treat cryoprecipitate mini-pools [10,11], this prepara-
tion does not routinely undergo pathogen inactivation [7,9].
Fibrinogen concentrate is considered to offer benefits over
cryoprecipitate in terms of higher purity, more accurate/s-
tandardized dosing, faster speed of preparation and admin-
istration, no need for blood group matching, decreased
allergic reactions and improved safety [7,9].
Currently, there is one main plasma-derived HFC indi-
cated for use in congenital fibrinogen deficiency and that
is widely available in a number of countries worldwide
[12,13]. A single virus inactivation step (pasteurization) is
used in the manufacture of this product [14–16].
A new HFC has been developed that undergoes two
virus inactivation/elimination steps: solvent/detergent (S/
D) treatment and nanofiltration. It is a freeze-dried,
plasma-derived concentrate of human fibrinogen. The
manufacturing process of this new product yields a
highly-purified fibrinogen concentrate with no stabilizers
added. This new HFC is currently undergoing evaluation
in a broad clinical development program, which includes
establishing the pharmacokinetics, efficacy and safety for
on-demand treatment and surgical prophylaxis in adult
and pediatric patients with congenital fibrinogen
deficiency [17,18].
Here, we present the results of the first phase of the
clinical development of this new HFC, a prospective, ran-
domized trial comparing single-dose pharmacokinetics,
efficacy and safety vs. a commercially available fibrinogen
concentrate as active control in congenital afibrinogene-
mia patients. Our aims were to assess and compare the
pharmacokinetic profiles as well as clot strength (by mea-
suring maximum clot firmness [MCF]; ROTEM throm-
boelastometry) as a surrogate measure of hemostatic
efficacy.
Materials and methods
FORMA-01 (NCT01575756) was a multinational, multi-
center, prospective, randomized, controlled, crossover,
phase II, pharmacokinetic study, conducted in accordance
with Good Clinical Practice (CPMP/ICH/135/95), the
European Directive 2001/20/EC and applicable regulatory
requirements, as well as the Declaration of Helsinki and
national law. Twenty-two patients with congenital fibrino-
gen deficiency were enrolled and treated in this study.
The study was conducted across 10 sites in six countries
(Bulgaria [one patient], India [eight patients, three sites],
Iran [seven patients, two sites], Switzerland [one patient],
UK [three patients, one site] and the USA [two patients,
two sites]) from June 2013 to January 2015. The study
protocol received written approval from the country regu-
latory authorities, Independent Ethics Committees and
Institutional Review Boards, in accordance with local
requirements.
The trial consisted of two study periods, each lasting
45 days. Subjects were randomized to receive a single infu-
sion of the new HFC (FIBRYGA, Octapharma AG,
Lachen, Switzerland) or active control (Haemocomplet-
tan P/RiaSTAPTM, CSL Behring GmbH, Marburg,
Germany) in both study periods. Crossover was performed
at the end of the first study period (Fig. 1). Randomiza-
tion took place before first study drug administration and
was performed using a computer-generated randomization
schedule to assign the patients, in a blinded manner and in
the order of their presentation across all centers, to
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treatment sequences. One central list balanced over all
patients was generated. The study was open-label after
randomization. The new HFC and active control were
supplied in vials containing 1 g of lyophilized fibrinogen
concentrate powder for reconstitution with 50 mL of water
for injection. Study medication was administered as an
intravenous infusion of 70 mg kg1 bodyweight1 accord-
ing to the label potency of the products.
Inclusion criteria and assessment schedule
The primary inclusion criteria were: age ≥ 12 years; docu-
mented congenital afibrinogenemia (i.e. plasma fibrinogen
activity and antigen at screening below the detection limit
[< 0.2 g L1]) from the central laboratory; and informed
consent signed by the patient or his or her legal guardian.
The primary exclusion criteria were: bleeding disorder
other than congenital fibrinogen deficiency; dysfibrinogen-
emia; treatment with any fibrinogen concentrate or other
fibrinogen-containing blood product in the 2 weeks prior
to enrolment and/or subsequent study treatment; presence
or history of thrombosis; acute bleeding; end-stage liver
disease (i.e. Child-Pugh score B or C); planned major sur-
gery with a need for blood transfusion during the pharma-
cokinetic blood-sampling period of this study; pregnancy
or the intention to become pregnant during the study; and
polytrauma 1 year prior to enrolment. Blood samples were
collected at baseline, at 0.5, 1, 2, 4 and 8 h, and on Days 2,
3, 5, 7, 10 and 14 after infusion of medication, and all
samples were tested in a central laboratory. The central
laboratory for fibrinogen measurements in plasma, throm-
bogenicity and MCF was at Lund University, Malm€o
University Hospital, Malm€o, Sweden, and was blinded
from treatment allocation, and the laboratory for virus
safety testing was INTERLAB central services–worldwide
GmbH in Munich, Germany. Octapharma’s quality con-
trol laboratory (Vienna, Austria) performed activity testing
on the fibrinogen concentrates.
Objectives
The primary objectives were to determine the single-dose
pharmacokinetic profile of the new HFC compared with
the active control, and to determine MCF as a surrogate
marker for hemostatic efficacy before and after adminis-
tration of either product in patients with congenital afib-
rinogenemia. The secondary objective was to assess the
safety of the new HFC in this population.
Pharmacokinetics
Fibrinogen activity was measured using a modified Clauss
assay validated in the central laboratory with a limit of
quantification of 0.2 g L1. The following pharmacoki-
netic parameters were assessed: area under the concentra-
tion-time curve (AUC), AUC normalized to the dose
administered according to the measured actual potency
(AUCnorm), in vivo half-life (t1/2), incremental in vivo
recovery (IVR), classical IVR, maximum plasma concen-
tration (Cmax), Cmax normalized to the dose administered
according to the measured actual potency (Cmaxnorm),
time to reach maximum plasma concentration (Tmax),
mean residence time (MRT), volume of distribution at
steady state (VSS) and clearance (CL). Incremental and
classical IVRs were calculated as the maximum increase
in plasma fibrinogen activity within 4 hours following
infusion when compared with pre-infusion plasma fibrino-
gen levels.
Efficacy: clot quality (maximum clot firmness)
Thromboelastometry (ROTEM, Tem International
GmbH, Munich, Germany) was used to measure MCF.
MCF is a functional parameter that depends on the acti-
vation of coagulation and the polymerization and cross-
linking of the fibrin network, and is usually measured in
whole blood. When measured in plasma, MCF primarily
depends on the fibrinogen content of the sample and the
resulting fibrin network. MCF in plasma was used as a
surrogate marker of hemostatic efficacy [8,19] at 1 h after
administration of either product.
All MCF measurements used frozen citrated plasma
samples and the exTEM activator, and were performed in
the central laboratory to minimize center-to-center vari-
ability. This methodology was used in a previous study of
fibrinogen concentrate [8].
Two-week
washout period
Active control
New HFC New HFC
Study end
Active control
Study period 1
(45 days)
Study period 2
(45 days)
Crossover
Fig. 1. The FORMA-01 study: single-dose pharmacokinetic crossover design. HFC, human fibrinogen concentrate. [Color figure can be viewed
at wileyonlinelibrary.com]
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis
and Haemostasis.
New concentrate for fibrinogen deficiency 255
Safety
Thrombogenicity measurements included prothrombin
fragments 1 and 2 (F1 + F2) and D-dimer performed
prior to infusion and at 0.5, 1, 2, 4 and 8 h post-infusion
on Day 1 of both study periods. Virus safety assessments
included testing for HIV-1 and HIV-2, hepatitis A virus
(HAV), hepatitis B virus (HBV), hepatitis C virus (HCV)
and parvovirus B19 (parvo B19) by serology and poly-
merase chain reaction (PCR) assessments. Early allergic
reactions and hypersensitivity were monitored and
recorded at all post-infusion visits for the first 2 days fol-
lowing any treatment with study medication.
Clinical safety was assessed by monitoring vital signs
(systolic and diastolic blood pressure, pulse rate, respira-
tory rate and body temperature) at predefined time-
points, and by monitoring laboratory parameters and
adverse events (AEs) throughout the study. Hematologi-
cal parameters included platelet count, hemoglobin and
hematocrit. Clinical chemistry parameters included ala-
nine aminotransferase (ALT), aspartate transaminase
(AST), gamma-glutamyl transpeptidase (GGT), alkaline
phosphatase, bilirubin total, creatinine and urea, and
serum electrolytes (sodium, potassium, bicarbonate and
calcium).
Adverse events (AEs) and serious adverse events
(SAEs) were reported from Day 1 to Day 45 in each
period.
Statistical methods
Because of the limited number of patients for this ultra-
rare indication, no formal sample size estimations were
performed. Instead, the sample size chosen on the basis
of study feasibility was shown to have sufficient power
for testing bioequivalence regarding AUC within a power
calculation that was performed prospectively, in advance
of the study start. Bioequivalence was defined as the ratio
of AUCs between treatments within the bound of 0.80 to
1.25, equivalent to a mean difference on the log scale
within the bound of 0.223 to +0.223. The within-subject
standard deviation for AUC (on the log scale) was esti-
mated to be 0.26. With a potential sample size of 18
evaluable patients, and assuming a 5% significance level,
the study was estimated to have > 90% power, assuming
a true ratio of 1 for the AUC between groups (equivalent
to a mean difference of 0 on the log scale). If the true
ratio was to be either 0.95 or 1.053 (equivalent to a mean
difference of 0.051 on the log scale), the power would still
have been over 80%.
Pharmacokinetic analyses were primarily performed in
the per-protocol analysis of 21 patients. This excluded
one patient who received < 90% of the planned total
dose of study medication. For comparison of the phar-
macokinetic parameters, 90% confidence intervals (CIs)
were calculated for the mean ratio of the new HFC over
active control for selected dose-independent or
dose-adjusted pharmacokinetic parameters. Based on
log-transformed AUCnorm, bioequivalence of the two
products was assessed using a 2 9 2 crossover analysis
of variance model (assuming independence and a normal
distribution for the patient effect and error, and treat-
ment effect and period effect as fixed effects) to test
whether the 90% CI for the mean ratio of AUCnorm
was within the range 0.8–1.25, as specified in the statisti-
cal calculations prior to the study start. The null
hypothesis was non-equivalence (AUCnorm ratio < 0.8 or
> 1.25). Following the observation of non-equivalence
for some pharmacokinetic parameters, tests of the null
hypothesis of no difference (ratio=1) were performed
post hoc using ANOVA type 3 tests of fixed effects in
order to further characterize any differences in the
pharmacokinetic parameters between the new HFC and
the active control. Descriptive P-values are provided
accordingly.
For comparison of hemostatic efficacy, prespecified
95% CIs were calculated for the mean difference in the 1-
h MCF plasma values between the two products. Safety
variables were analyzed descriptively. MCF and safety
were assessed in the full analysis patient dataset (n = 22).
Results
Patient characteristics
Twenty-seven patients were screened, of whom five were
screening failures and 22 patients were treated in the
study. In accordance with the inclusion criteria, patients
were older than 12 years of age, with a median (range)
age of 23 (12–53) years. Of the 22 patients, 14 (63.6%)
were of White race and eight (36.4%) were Asian; six
(27.3%) patients were between 12 and < 18 years old,
and 16 (72.7%) were aged ≥ 18 years (Table 1).
Table 1 Demographic and clinical characteristics (n = 22)*
Parameter Mean SD Median Range
Age at first study
treatment (years)
26.0 12.8 23.0 12–53
Height (cm) 161.7 14.4 159.5 130–190
Weight (kg) 65.7 17.8 69.1 33–107
BMI (kg m2) 24.9 4.8 25.6 14–34
N %
Age category
< 18 years 6 27.3
≥ 18 years 16 72.7
Gender
Male 7 31.8
Female 15 68.2
Race
White 14 63.6
Asian 8 36.4
BMI, body mass index; SD, standard deviation. *Full analysis
patient dataset.
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Pharmacokinetics and maximum clot firmness
The primary analyses were performed on data from 21
patients. At baseline, fibrinogen concentrations were at or
below the limit of detection of the assays in all patients,
as expected in this patient population. Actual mean (SD)
doses of study medication administered were 76.88 (0.60)
mg kg1 for the new HFC and 69.74 (0.71) mg kg1 for
the active control. Mean fibrinogen concentration normal-
ized to actual dose administered peaked within 2 h after
administration of the new HFC (1.161 g L1) and 30 min
of the active control (1.222 g L1), and for both groups
decreased to pre-infusion levels by 216 h (9 days) (Fig. 2).
Over the first 144 h (6 days), the mean plasma fibrinogen
concentrations measured for the new HFC showed higher
values than those observed with the active control
(Fig. 2).
In the per-protocol analysis (n = 21), the mean ratio of
the new HFC to active control for AUCnorm was 1.196
(90% CI, 1.117, 1.281) (Table 2). Analysis of the mean
ratio for AUCnorm in all patients (n = 22) showed compa-
rable results to the primary analysis (1.217; 90% CI,
1.133, 1.307). Consequently, bioequivalence was not
demonstrated for the primary endpoint of the study.
Bioequivalence was also not demonstrated for clearance,
with mean ratio of 0.836 (90% CI, 0.781, 0.895). Further-
more, for Vss, a mean ratio of 0.886 (90% CI 0.791,
0.994) was observed. For the remaining pharmacokinetic
parameters, the 90% CI for the mean ratios were within
the range 0.8–1.25, reflecting bioequivalence between the
two products (Table 2).
Values for pharmacokinetic parameters with each study
medication are shown in Table 3 (corresponding data for
all patients [n = 22] are provided in Table S1). In the
post-hoc analyses, the mean AUCnorm calculated for
fibrinogen activity was significantly larger for the new
HFC than for the active control (1.62  0.45 vs.
1.38  0.47 h kg g L1 mg1, P = 0.0002). For the two
remaining pharmacokinetic parameters that did not
demonstrate bioequivalence, clearance and Vss, ANOVA
only showed significant differences between products in
the mean value for clearance, which was significantly
slower for the new HFC compared with the active control
(0.665  0.197 vs. 0.804  0.255 mL h1 kg1,
P = 0.0002). These data indicate that the new HFC was
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Fig. 2. Mean ( SD) fibrinogen activity (g L1) during pharmacokinetic assessment after administration of new HFC or active control
(n = 21).* Fibrinogen activity plotted against time for the new HFC and active control following normalization to the dose administered and
standardization to 70 mg kg1. *Per protocol patient analysis set. HFC, human fibrinogen concentrate; LOQ, limit of quantification; SD, stan-
dard deviation. [Color figure can be viewed at wileyonlinelibrary.com]
Table 2 Ratios of new HFC over active control for AUC and other
pharmacokinetic parameters based on fibrinogen activity measured
in plasma samples (n = 21)*
Parameter
Mean
ratio†
90% CI of
mean ratio‡
AUCnorm 1.196 1.117, 1.281
AUC 1.319 1.232, 1.413
Cmaxnorm 0.989 0.927, 1.055
Cmax 1.091 1.023, 1.162
Incremental IVR 1.005 0.939, 1.075
Classical IVR 0.972 0.903, 1.045
t1/2 1.080 0.954, 1.224
MRT 1.061 0.944, 1.192
CL 0.836 0.781, 0.895
Vss 0.886 0.791, 0.994
ANOVA, analysis of variance; AUC, area under the concentration-
time curve; AUCnorm, area under the concentration-time curve nor-
malized to the dose administered; Cmax, maximum plasma concentra-
tion; Cmaxnorm, maximum plasma concentration normalized to the
dose administered; CI, confidence interval; CL, clearance; HFC,
human fibrinogen concentrate; IVR, in vivo recovery; MRT, mean
residence time; t1/2, half-life; Vss, volume of distribution at steady
state. *Per protocol patient analysis set. †Geometric mean derived
from the ANOVA model on log-transformed values. ‡Tested against
the null hypothesis of non-equivalence: 90% CI of the mean ratio
not contained with the range 0.8–1.25.
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at least as efficacious as the active control for increasing
fibrinogen activity. Furthermore, although the numbers
are small, mean values for AUCnorm and clearance for
the new HFC were similar in patients < 18 (n = 5) and
≥ 18 years old (n = 16) (AUCnorm, 1.573 and 1.640 h
kg g L1 mg1, respectively; clearance, 0.675 and
0.661 mL h1 kg1, respectively).
As expected, a significant increase in mean plasma
MCF from baseline (all 0.00 mm) to 1 h after administra-
tion was observed with the new HFC (9.68 mm) and with
active control (10.00 mm) (both P < 0.0001; Table 4).
The mean difference between the 1-hour post-infusion
MCF values was 0.32 mm (95% CI, 1.70, 1.07); the
confidence interval included zero, indicating that the dif-
ference between treatments was not significant (Fig. 3).
Safety
Adverse events generally occurred as single events in indi-
vidual patients. The incidence and nature of AEs after
administration of the new HFC and active control are
shown for all 22 patients in Table 5.
Two AEs occurring in two patients were considered to
be possibly related to the new HFC: one mild pyrexia
and one mild allergic skin reaction. One severe AE
Table 3 Pharmacokinetic parameters (fibrinogen activity) for new
HFC or active control measured in plasma samples (n = 21)*
Parameter
Treatment Mean SD Median Range
AUCnorm (h kg g L
1 mg1)
New HFC 1.62 0.45 1.59 0.85–2.51
Active control 1.38 0.47 1.24 0.76–2.46
AUCnorm, standardized to 70 mg kg
1 (g h L1)
New HFC 113.70 31.54 111.14 59.70–175.51
Active control 96.39 32.89 87.03 53.36–172.16
Cmaxnorm, kg g L
1 mg1
New HFC 0.018 0.005 0.018 0.01–0.03
Active control 0.018 0.005 0.017 0.01–0.03
Cmax, g L
1
New HFC 1.390 0.369 1.360 0.83–2.16
Active control 1.265 0.309 1.200 0.85–1.99
Cmax, standardized to 70 mg kg
1 (g h L1)
New HFC 1.266 0.338 1.236 0.75–1.96
Active control 1.271 0.312 1.217 0.85–1.99
Incremental IVR, mg dL1 increase per mg kg1
New HFC 1.787 0.458 1.766 1.08–2.62
Active control 1.770 0.442 1.700 1.21–2.84
Classical IVR, %
New HFC 64.397 11.519 64.830 40.89–88.13
Active control 66.046 11.635 66.756 50.17–92.46
Tmax, h
New HFC 2.148 1.475 2.000 0.50–4.08
Active control 1.417 2.054 0.500 0.45–8.00
t1/2, h
New HFC 75.940 23.831 72.854 40.03–156.96
Active control 69.378 16.006 64.644 48.60–101.94
MRT, h
New HFC 106.272 30.927 98.975 58.72–205.47
Active control 98.977 20.812 93.462 72.38–141.21
CL, mL h1 kg1
New HFC 0.665 0.197 0.630 0.40–1.17
Active control 0.804 0.255 0.804 0.41–1.31
Vss, mL kg
1
New HFC 70.158 29.860 61.037 36.89–149.11
Active control 76.631 19.579 77.701 47.89–113.68
AUC, area under the concentration-time curve; AUCnorm, area
under the concentration-time curve normalized to the dose adminis-
tered; Cmax, maximum plasma concentration; Cmaxnorm, maximum
plasma concentration normalized to the dose administered; CL,
clearance; HFC, human fibrinogen concentrate; IVR, in vivo recov-
ery; MRT, mean residence time; SD, standard deviation; t1/2, half-
life; Tmax, time to reach maximum plasma concentration; Vss, volume
of distribution at steady state. *Per protocol patient analysis set.
Table 4 MCF measured in plasma samples at baseline and 1 h after
infusion of new HFC or active control (n = 22)*
Concentrate
MCF at
baseline (mm)
MCF at
1 hour (mm)
Change in
MCF from
baseline to
1 hour (mm)
Mean  SD
Median (range)
Mean  SD
Median (range) 95% CI
New HFC 0  0
0 (0–0)
9.68  2.950†
10.00 (4.0–16.0)
8.37, 10.99
Active control 0  0
0 (0–0)
10.00  4.353
10.50 (0.0–17.0)‡
8.07, 11.93
CI, confidence interval; HFC, human fibrinogen concentrate; MCF,
maximum clot firmness; SD, standard deviation. *Full analysis
patient dataset. †Relative to active control: mean difference 0.32,
95% CI 1.70, 1.07 (not statistically significant). ‡Tested MCF for
one patient was 0, despite this patient displaying a significant rise in
fibrinogen levels at the same time-point. Upon evaluation, this was
the result of a technical issue with the sample prior to MCF
analysis.
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Fig. 3. Box plot of change from baseline to 1-hour after administra-
tion of new HFC or active control for MCF values in plasma sam-
ples (n = 22).* The box plot shows the median (horizontal line),
mean (diamond), upper and lower quartiles (box ends), and mini-
mum and maximum (whiskers) within 1.5-times the interquartile
range. *Full analysis patient dataset. HFC, human fibrinogen con-
centrate; MCF, maximum clot firmness. [Color figure can be viewed
at wileyonlinelibrary.com]
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(urinary tract infection) occurred 6 days after infusion of
the new HFC but was not considered to be related to
treatment. One patient experienced two SAEs on the
same day (abdominal pain and vaginal hemorrhage),
25 days after receiving the new HFC; these events were
also not considered to be treatment related.
No deaths occurred following administration of either
study medication and no severe allergic reactions, cases of
thromboembolism or clinically relevant changes in pro-
thrombin F1 + F2 and D-dimer relative to pre-infusion
levels were observed. No clinically abnormal vital signs
were observed during the study, and there were no sero-
conversions for HIV, HAV, HBV, HCV or parvovirus
B19 after infusion of either product. No clinically signifi-
cant abnormalities in clinical chemistry parameters were
recorded with either HFC.
Discussion
This phase II, randomized trial in congenital afibrino-
genemia patients represents the first phase of the clinical
development of a new fibrinogen concentrate, and com-
pared single-dose pharmacokinetics, efficacy and safety
of this newly developed fibrinogen concentrate vs. a
commercially available fibrinogen concentrate. The study
found broadly comparable pharmacokinetic profiles of
the two fibrinogen concentrates, except that the bioe-
quivalence criteria for the primary endpoint AUCnorm
and for the pharmacokinetic parameters clearance and
Vss were not reached, and demonstrated a statistically
significant increase in fibrin clot quality after infusion,
which translates into a potential to promote hemostasis
in bleeding situations. The post-hoc ANOVA analyses on
the pharmacokinetic parameters that did not reflect bioe-
quivalence showed significant differences between the
treatments for the area under the concentration-time
curve, which was significantly larger, and for clearance,
which was significantly slower, with the new HFC vs.
the active control. Maximum clot firmness was
significantly increased at 1 h post-infusion with both
products, demonstrating similar efficacy in restoring clot
strength. Both products showed a favorable safety pro-
file with no deaths, thrombotic events, severe allergic
reactions or viral seroconversions related to either treat-
ment.
Plasma fibrinogen concentration peaked within 2 h
after administration with both products, and levels
achieved were well within the recommended target (1–
1.5 g L1) [6] and very similar to those observed in a pre-
vious study performed with the active control (median of
1.3 g L1) [8]. The observations that bioequivalence crite-
ria were not reached for AUCnorm and that the new HFC
showed a significantly larger AUCnorm vs. the active
control were surprising. Although the corresponding
Cmaxnorm values were similar between the two concen-
trates, some differences were observed in their respective
pharmacokinetic profiles. Plasma fibrinogen concentration
peaked earlier after administration of active control (me-
dian Tmax 0.5 h), whereas the peak after HFC was flatter,
with a median Tmax of 2.0 h. Following this initial phase,
elimination of the two concentrates was almost parallel;
t1/2 was slightly longer with HFC vs. active control, but
within the range of bioequivalence. Thus, the initial dif-
ference in the pharmacokinetic profiles could be the main
determinant of the higher AUCnorm with HFC when com-
pared with the active control. Another potential cause of
this difference may be the slower clearance observed,
which could imply enhanced persistence of the new HFC
in the circulation due to increased product purity,
although the mechanism for this requires further study.
As for the comparison with data published so far, most
pharmacokinetic measurements were broadly in line with
values reported in previous studies of fibrinogen concen-
trates [8,20]. Slight differences in individual parameters,
for instance median t1/2 of 77.1 h for the active control
reported by a previous study [8], compared with 64.6 h
observed in the current study, might be due to the vari-
ability brought about by the small sample sizes used in
both studies. Nevertheless, given the robustness of the
crossover design of the current study, these results should
provide an accurate indication of the differences between
the two products.
MCF has been established in in vitro and clinical stud-
ies of patients with congenital fibrinogen deficiency as a
good marker for the global quality and integrity of the
clotting process following administration of fibrinogen
concentrate [8,19]. The rapid increases in MCF we
observed after a single infusion of medication were con-
sistent with that seen in a previous study [8]. The
observed changes in MCF values also closely matched the
levels expected from in vitro spiking experiments per-
formed using plasma samples from individuals with fib-
rinogen deficiency and known amounts of exogenous
fibrinogen [19]. The increase in MCF using exTEM acti-
vator in citrated plasma samples is very encouraging, but
Table 5 Summary of adverse events (all patients, n = 22)*
N (%) of patients, Number of
events
New HFC Active control
AEs 11 (50.0), 25 11 (50.0), 30
Severity of AE
Mild 8 (36.4), 15 9 (40.9), 26
Moderate 5 (22.7), 9 3 (13.6), 4
Severe 1 (4.5), 1 0
Probably or possibly related AE 2 (9), 2 0
AE leading to withdrawal 0 0
SAE 1 (4.5), 2 0
Death 0 0
AE, adverse event; HFC, human fibrinogen concentrate; SAE, seri-
ous adverse event. *Full analysis patient dataset.
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it must be kept in mind that results obtained using
plasma are not equivalent to results obtained using whole
blood, which is more commonly used in clinical practice,
in particular in the settings of perioperative bleeding and
trauma. It cannot be estimated what impact fibrinogen
supplementation would have had on whole blood
ROTEM analyses. Whole blood ROTEM analyses are
challenging for multicenter studies in congenital afibrino-
genemia; the rarity of the disease and its variability in
geographic distribution, together with the need for user
training and quality control, make centralized testing of
plasma samples more applicable for the congenital fib-
rinogen deficiency setting.
Regarding safety, we observed favorable profiles for
both the new HFC and the active control, the latter being
an established human fibrinogen concentrate product with
extensive pharmacovigilance data collected since it first
became commercially available 30 years ago [21]. Adverse
events generally occurred as single events in individual
patients. There were no deaths, thrombotic events or sev-
ere allergic reactions in the study, nor were there serocon-
versions related to either treatment. These findings are in
line with data reported previously, which indicate a low
rate of adverse events following use of fibrinogen concen-
trate in populations including patients with inherited defi-
ciency [8,21].
Our study has some limitations. With 22 patients
included in the analysis, the patient cohort may be con-
sidered small, although the randomized crossover design
is a rigorous test of the comparison and the study was
well powered to test bioequivalence. Given that afibrino-
genemia is a very rare bleeding disorder, our study popu-
lation was relatively large compared with previous studies
conducted in this setting [8,15,20]. There were limitations
regarding the efficacy and safety analyses: the assessment
of hemostatic efficacy was carried out through the
surrogate measure of MCF, and the study was not pow-
ered to formally compare the safety of the two fibrinogen
concentrates.
Further studies will need to incorporate direct mea-
sures of clinical efficacy. For example, the primary out-
come measure of the ongoing phase III FORMA-02
study (NCT02267226) is clinical assessment of the
hemostatic efficacy of the new HFC in treating acute
bleeding episodes (spontaneous or after trauma) in
patients aged ≥ 12 years with congenital afibrinogenemia
or severe hypofibrinogenemia [17]. These data, together
with data from the ongoing phase III FORMA-04 pedi-
atric study (NCT02408484) [18], will provide a better
understanding of how the pharmacokinetic and plasma
MCF findings from the current study translate into the
bleeding and perioperative setting, where prompt cessa-
tion of bleeding and restoration of hemostasis are
required.
In conclusion, this randomized, controlled, single-dose,
crossover trial showed that the new HFC did not reach
the bioequivalence criteria for the primary endpoint of
the study, AUCnorm. From the remaining pharmacoki-
netic parameters, the same was observed for clearance
and Vss. ANOVA analyses on these parameters showed a
significantly larger AUCnorm and slower clearance when
compared with another fibrinogen concentrate. The new
HFC significantly increased clot strength 1 h after dosing,
to a similar degree to the active control. The safety and
tolerability profile was favorable. Additional investiga-
tions will be required to ascertain the mechanism and
potential clinical impact of the favorable pharmacokinetic
profile observed with this new concentrate. In the mean-
time, these results suggest the profile of this product to be
effective for raising fibrinogen levels and correcting the
clotting ability of the blood, features that are needed in
the treatment and prevention of bleeding in adult and
pediatric patients with congenital fibrinogen deficiency.
Clinical treatment studies with the new fibrinogen concen-
trate are ongoing.
Addendum
C. Ross, S. Rangarajan, M. Karimi, G. Toogeh, S. Apte,
T. Lissitchkov, S. Acharya, M. J. Manco-Johnson, A. Sri-
vastava, B. Brand, B. A. Schwartz, S. Knaub and F. Pey-
vandi were responsible for the concept and design;
analysis and/or interpretation of data; critical writing or
revision of the intellectual content; and final approval of
the version to be published.
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